| 翻訳と辞書 |
Cavatak
Cavatak is the trade name for a preparation of wild-type Coxsackievirus A21 (CVA21) developed by the Australian biotechnology company Viralytics Ltd. for the treatment of malignant melanoma and other cancers such as breast, prostate and head and neck cancer.
== Pre-clinical research ==
Within the ''Picornaviradae'' family of viruses, Coxsackievirus A21 (CVA21) is a member of the Human enterovirus C species. The virus consists of a single positive-stranded RNA genome within a capsid of approximately 28 nm in diameter.
The virus is known to utilise the viral entry receptor ICAM-1 as its primary entry receptor, with DAF as a co-receptor to infect host cells. Traditionally known as a common-cold virus that causes mild upper respiratory tract infections, the anti-cancer properties of this virus for the destruction of malignant melanoma cells was first published in 2004. The proposed mechanism of CVA21 oncolysis is through the preferential targeting of melanoma cells that over-express the molecules ICAM-1 and/or DAF compared to normal cells.
CVA21 has also been found to have preclinical activity against breast and prostate cancer and multiple myeloma.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Cavatak」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|